India Immune-Oncology Drugs Market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others) was valued at US$ 172.8 million in 2018 and is projected to exhibit a CAGR of 13.1% over the forecast period (2018 - 2026).

Increasing cancer research, new product launches, sales and marketing approvals, and rising number of development programs are major factors expected to drive growth of the India immune-oncology drugs market. Various organizations are focused on launching new products to aid India immune-oncology drugs market to gain fair share in the market. For instance, in July 2018, Dr. Reddy’s Laboratories Ltd. launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India. It is indicated for the treatment of HER2-positive cancer (early breast cancer, metastatic breast cancer, and metastatic gastric cancer). Moreover, in November 2017, Biocon launched Krabeva, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian, and brain cancers, in India.

Furthermore, some companies are engaged in receiving sales and marketing approvals from regulatory bodies of India to import their products, which can further increase India immune-oncology drugs market size. For instance, in June 2018, AstraZeneca Pharma India Limited received Import & Market permission for Durvalumab (Imfinzi) in India, by the Drug Controller General of India (DCGI) Manufacturers in India immune-oncology drugs market are focusing on strategic collaboration, in order to gain significant market share. For instance, in September 2016, Dr. Reddy’s Laboratories Ltd., expanded its strategic collaboration with Amgen to market and distribute Amgen’s three drugs (XGEVA ( denosumab), Vectibix (panitumuma), and Prolia (denosumab)), in India for the treatment of oncology and osteoporosis. Bristol-Myers Squibb emphasizes on collaborations with other biopharmaceutical and pharmaceutical companies to advance their own research on novel compounds. For instance, AbbVie and Bristol-Myers Squibb collaborated in 2017, for research on Opdivo and ABBV-399. Bristol-Myers-Squibb and Seattle Genetics collaborated for research on Adcetris (brentuximab) and Opdivo (Nivolumab) for the treatment of relapsed or refractory Hodgkin lymphoma.

Browse 38 Market Data Tables and 21 Figures spread through 162 Pages and in-depth TOC on "India immune-oncology drugs market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others)- Global Forecast to 2026"

To know the latest trends and insights related to India Immune-Oncology Drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

AstraZeneca Plc is engaged in creating awareness among the Indian community, in order to increase its market share in India. For instance, in February 2018, AstraZeneca Pharma India Limited and Indian Cancer Society launched a nationwide cancer awareness initiative – Cancer Screening for Women. Under this program, free, specialized cancer-screening was conducted across the country for women from underprivileged families.

Key Takeaways of the India Immune-Oncology Drugs Market:

  • India immune-oncology drugs market is expected to expand at a CAGR of 13.1% during the forecast period (2018–2026), owing to increasing research & development and demand for genomic and repertoire sequencing-based research.
  • Among drug type, Monoclonal Antibodies segment is expected to hold major revenue share in 2026, owing to increasing number of product launches. For instance, in August 2014, India-based generics maker Hetero Group (Hetero) launched its biosimilar ‘Rituximab’ under the brand name MABALL, in India. Rituximab is recommended as the first-line treatment for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL) and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.
  • Major players operating in India immune-oncology drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner